A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

Hilal S. Khalil, Simon P. Langdon, Alexey Goltsov, Tero Soininen, David J. Harrison, James L. Bown, Yusuf Y. Deeni

    Research output: Contribution to journalArticle

    12 Citations (Scopus)
    15 Downloads (Pure)

    Abstract

    Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation and signaling. A combination of HER2 targeting monoclonal antibodies shows greater anticancer efficacy than the single targeting antibodies, however, its mechanism of action is largely unclear. Here we report novel actions of anti-HER2 drugs, Trastuzumab and Pertuzumab, involving NRF2. HER2 targeting by antibodies inhibited growth in association with persistent generation of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in NRF2 levels and inhibition of NRF2 function in ovarian cancer cell lines. The combination of antibodies produced more potent effects than single alone; downregulated NRF2 substrates by repressing the Antioxidant Response (AR) pathway with concomitant transcriptional inhibition of NRF2. We showed the antibody combination produced increased methylation at the NRF2 promoter consistent with repression of NRF2 antioxidant function, as HDAC and methylation inhibitors reversed such produced transcriptional effects. These findings demonstrate a novel mechanism and role for NRF2 in mediating the response of cancer cells to the combination of Trastuzumab and Pertuzumab and reinforce the importance of NRF2 in drug resistance and as a key anticancer target.
    Original languageEnglish
    Pages (from-to)75874-75901
    Number of pages28
    JournalOncotarget
    Volume7
    Early online date4 Oct 2016
    DOIs
    Publication statusPublished - 15 Nov 2016

    Fingerprint

    Ovarian Neoplasms
    Immunotherapy
    Antibodies
    Methylation
    Antioxidants
    Neoplasms
    Histone Deacetylase Inhibitors
    Receptor Protein-Tyrosine Kinases
    Growth
    Drug Resistance
    Glutathione
    Reactive Oxygen Species
    Down-Regulation
    Monoclonal Antibodies
    Cell Line
    Pharmaceutical Preparations
    Trastuzumab
    pertuzumab
    Therapeutics

    Cite this

    Khalil, Hilal S. ; Langdon, Simon P. ; Goltsov, Alexey ; Soininen, Tero ; Harrison, David J. ; Bown, James L. ; Deeni, Yusuf Y. / A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. In: Oncotarget. 2016 ; Vol. 7. pp. 75874-75901.
    @article{32cbaceffce14dd3b76cd63e6c70bafc,
    title = "A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells",
    abstract = "Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation and signaling. A combination of HER2 targeting monoclonal antibodies shows greater anticancer efficacy than the single targeting antibodies, however, its mechanism of action is largely unclear. Here we report novel actions of anti-HER2 drugs, Trastuzumab and Pertuzumab, involving NRF2. HER2 targeting by antibodies inhibited growth in association with persistent generation of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in NRF2 levels and inhibition of NRF2 function in ovarian cancer cell lines. The combination of antibodies produced more potent effects than single alone; downregulated NRF2 substrates by repressing the Antioxidant Response (AR) pathway with concomitant transcriptional inhibition of NRF2. We showed the antibody combination produced increased methylation at the NRF2 promoter consistent with repression of NRF2 antioxidant function, as HDAC and methylation inhibitors reversed such produced transcriptional effects. These findings demonstrate a novel mechanism and role for NRF2 in mediating the response of cancer cells to the combination of Trastuzumab and Pertuzumab and reinforce the importance of NRF2 in drug resistance and as a key anticancer target.",
    author = "Khalil, {Hilal S.} and Langdon, {Simon P.} and Alexey Goltsov and Tero Soininen and Harrison, {David J.} and Bown, {James L.} and Deeni, {Yusuf Y.}",
    year = "2016",
    month = "11",
    day = "15",
    doi = "10.18632/oncotarget.12425",
    language = "English",
    volume = "7",
    pages = "75874--75901",
    journal = "Oncotarget",
    issn = "1949-2553",
    publisher = "Impact Journals",

    }

    A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. / Khalil, Hilal S.; Langdon, Simon P.; Goltsov, Alexey; Soininen, Tero; Harrison, David J.; Bown, James L.; Deeni, Yusuf Y.

    In: Oncotarget, Vol. 7, 15.11.2016, p. 75874-75901.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

    AU - Khalil, Hilal S.

    AU - Langdon, Simon P.

    AU - Goltsov, Alexey

    AU - Soininen, Tero

    AU - Harrison, David J.

    AU - Bown, James L.

    AU - Deeni, Yusuf Y.

    PY - 2016/11/15

    Y1 - 2016/11/15

    N2 - Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation and signaling. A combination of HER2 targeting monoclonal antibodies shows greater anticancer efficacy than the single targeting antibodies, however, its mechanism of action is largely unclear. Here we report novel actions of anti-HER2 drugs, Trastuzumab and Pertuzumab, involving NRF2. HER2 targeting by antibodies inhibited growth in association with persistent generation of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in NRF2 levels and inhibition of NRF2 function in ovarian cancer cell lines. The combination of antibodies produced more potent effects than single alone; downregulated NRF2 substrates by repressing the Antioxidant Response (AR) pathway with concomitant transcriptional inhibition of NRF2. We showed the antibody combination produced increased methylation at the NRF2 promoter consistent with repression of NRF2 antioxidant function, as HDAC and methylation inhibitors reversed such produced transcriptional effects. These findings demonstrate a novel mechanism and role for NRF2 in mediating the response of cancer cells to the combination of Trastuzumab and Pertuzumab and reinforce the importance of NRF2 in drug resistance and as a key anticancer target.

    AB - Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation and signaling. A combination of HER2 targeting monoclonal antibodies shows greater anticancer efficacy than the single targeting antibodies, however, its mechanism of action is largely unclear. Here we report novel actions of anti-HER2 drugs, Trastuzumab and Pertuzumab, involving NRF2. HER2 targeting by antibodies inhibited growth in association with persistent generation of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in NRF2 levels and inhibition of NRF2 function in ovarian cancer cell lines. The combination of antibodies produced more potent effects than single alone; downregulated NRF2 substrates by repressing the Antioxidant Response (AR) pathway with concomitant transcriptional inhibition of NRF2. We showed the antibody combination produced increased methylation at the NRF2 promoter consistent with repression of NRF2 antioxidant function, as HDAC and methylation inhibitors reversed such produced transcriptional effects. These findings demonstrate a novel mechanism and role for NRF2 in mediating the response of cancer cells to the combination of Trastuzumab and Pertuzumab and reinforce the importance of NRF2 in drug resistance and as a key anticancer target.

    U2 - 10.18632/oncotarget.12425

    DO - 10.18632/oncotarget.12425

    M3 - Article

    VL - 7

    SP - 75874

    EP - 75901

    JO - Oncotarget

    JF - Oncotarget

    SN - 1949-2553

    ER -